3.9 Review

Metastasis in renal cell carcinoma: Biology and implications for therapy

期刊

ASIAN JOURNAL OF UROLOGY
卷 3, 期 4, 页码 286-292

出版社

ELSEVIER SINGAPORE PTE LTD
DOI: 10.1016/j.ajur.2016.08.006

关键词

Renal cell carcinoma; Metastasis; Vascular endothelial growth factor; Mammalian target of rapamycin; Hypoxia inducible factor

资金

  1. Pfizer
  2. Novartis
  3. Aveo
  4. Genentech
  5. Exelixis
  6. BMS
  7. Astellas
  8. GSK

向作者/读者索取更多资源

Although multiple advances have been made in systemic therapy for renal cell carcinoma (RCC), metastatic RCC remains incurable. In the current review, we focus on the underlying biology of RCC and plausible mechanisms of metastasis. We further outline evolving strategies to combat metastasis through adjuvant therapy. Finally, we discuss clinical patterns of metastasis in RCC and how distinct systemic therapy approaches may be considered based on the anatomic location of metastasis. (C) 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据